

Supplementary Materials

Montmorillonite-Sodium Alginate Oral Colon-Targeting Microcapsule Design for WGX-50 Encapsulation and Controlled Release in Gastro-Intestinal Tract

Yibei Jiang ¹, Zhou Wang ¹, Ke Cao ², Lu Xia ³, Dongqing Wei ^{4,*} and Yi Zhang ^{1,*}

¹ Department of Inorganic Materials, School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China; 215611016@csu.edu.cn (Y.J.); zhouwang@csu.edu.cn (Z.W.)

² Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha 410078, China; csucaoke@163.com

³ Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China; xialu@sklmg.edu.cn

⁴ State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China

* Correspondence: yee_z10@csu.edu.cn (Y.Z.); dqwei@sjtu.edu.cn (D.W.)

Citation: Jiang, Y.; Wang, Z.; Cao, K.; Xia, L.; Wei, D.; Zhang, Y. Montmorillonite-Sodium Alginate Oral Colon-Targeting Microcapsule Design for WGX-50 Encapsulation and Controlled Release in Gastro-Intestinal Tract. *J. Funct. Biomater.* **2023**, *15*, 3. <https://doi.org/10.3390/jfb15010003>

Academic Editor: Pankaj Vadgama

Received: 20 October 2023

Revised: 9 December 2023

Accepted: 11 December 2023

Published: 19 December 2023

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure S1. Freeze-dried microcapsules (A–B) and oven-dried microcapsules (C–D).




Figure S2. FTIR of SA, MMT, MMT₁-SA₃, MMT₃-SA₅ and MMT₁-SA₂ microcapsule.




Figure S3. TG-DSC curves for (A) MMT, (B) MMT₁-SA₁₉, (C) MMT₁-SA₇, (D) MMT₁-SA₃ and (E) MMT₃-SA₅.




Figure S4. Zeta potentials of MMT₁-SA₄, MMT₁-SA₆, MMT₁-SA₈ in different pH.




Figure S5. Cytotoxicity evaluation of MMT-SA to (A) HIEC-6 cells and (B) NCM-460 cells.




Figure S6. FTIR of WGX-50, MMT-SA and WGX-50/MMT-SA microcapsule.




Figure S7. TG (A) and DSC (B) of MMT, MMT-SA, WGX-50 and WGX-50/MMT-SA microcapsule.

Table S1. The mixed mass ratios and labels of MMT-SA microcapsule.

Samples	Sodium Alginate(mg)	MMT(mg)
MTT	0	200
MMT ₁ -SA ₁₉	10	190
MMT ₁ -SA ₇	25	175
MMT ₁ -SA ₃	50	150
MMT ₃ -SA ₅	75	125
MMT ₁ -SA ₂	75	150
MMT ₁ -SA ₄	75	300
MMT ₁ -SA ₆	75	450
MMT ₁ -SA ₈	75	600

Table S2. In vitro release data of WGX-50.

Theoretical value of WGX-50 (mg)	WGX-50 Encapsulation (mg)	WGX-50/MMT-SA (mg)	EE (%)	SD	DL (%)	SD
25	24.81	435.8	99.25	1.25E-4	5.71	5.57E-4
50	49.80	493.5	99.60	1.38E-4	10.09	1.40E-3
100	99.62	497.2	99.62	9.65E-5	20.04	2.89E-3
200	199.34	634.43	99.67	2.31E-5	31.43	6.53E-3

Table S3. Fitting results of WGX-50 release kinetics parameters using different models at pH 1.2, 6.8 and 7.4.

Release condition	Zero-order		First-order		Higuchi		Korsmeyer-Peppas	
	R ²	k	R ²	k	R ²	k	R ²	n
pH 1.2	0.985	0.0321	0.978	5.540E-5	0.990	0.501	0.980	1.062
pH 6.8	0.917	0.0171	0.774	3.046E-6	0.941	5.122	0.881	1.580
pH 7.4	0.0255	4.210E-4	0.719	0.00857	0.0628	0.0404	0.122	0.013